Publications by authors named "Lisa Heppler"

Claim this Profile
C
ClinVar Database Evolution and Impact on Potential Pathogenic Germline Variant Reporting from Tumor Comprehensive Genomic Profiling.
Allison W Kurian, Erica Gornstein, Lisa Heppler, Kali Chatham Dougherty, Rachel B Keller-Evans

Cancer Res Commun· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The antimicrobial drug pyrimethamine inhibits STAT3 transcriptional activity by targeting the enzyme dihydrofolate reductase.
Lisa N Heppler, Sanaz Attarha, Rosanne Persaud, Jennifer I Brown, Peng Wang

J Biol Chem· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses.
Jennifer R Brown, Sarah R Walker, Lisa N Heppler, Svitlana Tyekucheva, Erik A Nelson

Am J Hematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly-l-glutamic Acid-coated Layer-by-Layer Nanoparticles.
Isidora Tošić, Lisa N Heppler, Susana P Egusquiaguirre, Natalie Boehnke, Santiago Correa

Mol Cancer Ther· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation.
Alexandra M Stevens, Michael Xiang, Lisa N Heppler, Isidora Tošić, Kevin Jiang

Blood Adv· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibit versus Destroy: Are PROTAC Degraders the Solution to Targeting STAT3?
Lisa N Heppler, David A Frank

Cancer Cell· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rare mutations provide unique insight into oncogenic potential of STAT transcription factors.
Lisa N Heppler, David A Frank

J Clin Invest· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Oncogenic Transcription Factors: Therapeutic Implications of Endogenous STAT Inhibitors.
Lisa N Heppler, David A Frank

Trends Cancer· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent.
Michael Xiang, Haesook Kim, Vincent T Ho, Sarah R Walker, Michal Bar-Natan, Lisa N Heppler

Blood· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histone deacetylase 6 (HDAC6) promotes the pro-survival activity of 14-3-3ζ via deacetylation of lysines within the 14-3-3ζ binding pocket.
Jeffrey B Mortenson, Lisa N Heppler, Courtney J Banks, Vajira K Weerasekara, Matthew D Whited

J Biol Chem· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis